Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBT Margin (2018 - 2025)

Sunshine Biopharma's EBT Margin history spans 9 years, with the latest figure at 63.79% for Q4 2025.

  • For Q4 2025, EBT Margin rose 1998.0% year-over-year to 63.79%; the TTM value through Dec 2025 reached 3.44%, up 23.0%, while the annual FY2025 figure was 3.44%, 23.0% up from the prior year.
  • EBT Margin reached 63.79% in Q4 2025 per SBFM's latest filing, up from 10.84% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 783.75% in Q4 2021 to a low of 15440.43% in Q1 2021.
  • Average EBT Margin over 5 years is 1561.11%, with a median of 15.69% recorded in 2024.
  • Peak YoY movement for EBT Margin: tumbled -1459140bps in 2021, then skyrocketed 1443245bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 783.75% in 2021, then plummeted by -175bps to 590.86% in 2022, then skyrocketed by 98bps to 13.41% in 2023, then skyrocketed by 427bps to 43.81% in 2024, then skyrocketed by 46bps to 63.79% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBT Margin are 63.79% (Q4 2025), 10.84% (Q3 2025), and 21.04% (Q2 2025).